The second study72 found the same G101V substitution in four patients with recurrent CLL, one of which had tumour cells with a second, independent Bcl-2 variant containing a substitution of aspartate 103 to tyrosine, again within the BH3-binding pocket. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.